ABSTRACT 5-Bromodeoxycytidine is phosphorylated to 5-bromodeoxycytidine 5'-monophosphate in extracts of cells infected with herpes simplex virus but not in extracts of uninfected cells. The conversion of 5-bromodeoxycytidine to nucleotides and its utilization for DNA synthesis in uninfected cells occurs by deamination of 5-bromodeoxycytidine to 5-bromodeoxyuridine followed by phosphorylation of 5-bromodeoxyuridine to 5-bromodeoxyuridine 5'-monophosphate. In contrast, in cells infected with herpes simplex virus, 5-.bromodeoxycytidine is phosphorylated directly to 5-bromodeoxycytidine 5'-monophosphate, which can then be deaminated to 5-bromodeoxyuridine 5'-monophosphate and incorporated into DNA. These results indicate a difference in the substrate specificity of nucleoside kinases induced by herpes simplex virus and the enzymes present in uninfected cells. It is suggested that this difference in substrate specificity between virusinduced and host-cell enzymes may allow selective chemotherapy of herpes simplex infections with 5-bromo-or 5-iododeoxycytidine.
Several enzymes related to DNA synthesis, including thymidine kinase (1-3), deoxycytidine kinase (4) (5) (6) , deoxycytidylate deaminase (7), ribonucleotide reductase (8) , and DNA polymerase (7) , are induced in cells infected with herpes simplex virus (HSV). The synthesis of virus-induced enzymes in HSVinfected cells suggests the possibility of selective antiviral chemotherapy based on biochemical differences between HSVinduced and host-cell enzymes. Evidence presented in this paper indicates that 5-bromodeoxycytidine (BrdC) is readily phosphorylated by extracts of HSV-infected cells, whereas BrdC is a poor substrate for phosphorylation by extracts of uninfected cells. This difference in substrate specificity between HSV-induced and host-cell nucleoside kinases may contribute to selective chemotherapy of HSV infections.
BrdC is incorporated into the DNA of uninfected mouse cells as BrdUMP (9) . The conversion of BrdC to BrdUMP could occur by two pathways: (i) deamination of BrdC to BrdU followed by phosphorylation to BrdUMP, and/or (ii) phosphorylation of BrdC to BrdCMP followed by deamination to BrdUMP. These reactions could be catalyzed by the sequential actions of (i) cytidine deaminase (EC 3.5.4.5) and thymidine kinase (EC 2.7.1.21), and (ii) deoxycytidine kinase and deoxycytidylate deaminase. Mutant lines of mouse cells lacking thymidine kinase, and therefore resistant to BrdU, are also resistant to BrdC (9) . In addition, Cooper and Greer (10) showed that inhibition of cytidine deaminase in vivo reduces the incorporation of BrdC into the DNA of mouse tissues. These results suggest that the conversion of BrdC to cytotoxic nucleotides, and the utilization of BrdC for DNA synthesis, occur mainly by deamination of BrdC to BrdU followed by phosphorylation of BrdU by thymidine kinase.
Cooper and Greer (11) found that BrdC and IdC are poor substrates for deoxycytidine kinase in extracts of mouse and human lymphoid cells. Cervical Carcinoma Specimen&. Two cervical carcinoma specimens (stage 1B) were removed from women, 27 and 59 years of age, who had not received previous radiation therapy. The tumors were diagnosed as invasive squamous cell carcinoma by the Department of Pathology, Jackson Memorial Hospital, Miami. Tissues were used for enzyme extraction immediately after they were obtained from surgery.
HSV Infection. Monolayers of BHK or HEp-2 cells were infected with HSV diluted in growth medium. An inoculum of 1.0 ml was used to infect cells in 100-mm dishes and an inoculum of 0.25 ml for cells in 60-mm dishes. After two hours at 370 the inoculum was aspirated, the cells were washed with growth medium, fresh medium was added, and the cells were incubated at 37°.
Preparation of Cell Extracts and Enzyme Assays. Cells were washed twice with 0.9% NaCl; suspended in preparative buffer (1-5 X 107 cells/ml), and disrupted by sonication. Cervical carcinoma tissue (1 g) was homogenized in 5 ml of buffer in a Sorvall omnimixer. Extracts were centrifuged at 100,000 X g for 1 hr and the supernatant fluid was used immediately for enzyme assays. Protein was determined by the method of Lowry et al. (17) .
Maximal deoxycytidine kinase activity from cells infected with HSV-1 strains F and 2BB was obtained when extracts were prepared in buffer consisting of 25 mM Tris-HCl (pH (0) Reaction mixtures for determination of cytidine deaminase were as described above except that ATP was omitted. After incubation at 370, reactions were terminated by boiling. Aliquots (20 M1) of the reaction mixtures were applied to Whatman DE81 chromatography paper along with carrier unlabeled nucleosides (either dC and dU or BrdC and BrdU).
Chromatograms were developed with 0.03 N formic acid.
The positions of carrier nucleosides were identified under UV light, and the UV-absorbing areas were cut out and counted. The RF values of dC, BrdC, dU, and BrdU were 0.8, 0.7, 0.5, and 0.1, respectively. DNA hydrolysates were prepared after 107 HSV-infected BHK cells were labeled as described above. Cells were washed twice with 0.9% NaCl and three times with cold 5% perchloric acid. Precipitates were collected in 5% perchloric acid, washed with 95% ethanol, and dried in a vacuum desiccator. Nucleic acids were hydrolyzed in 0.1 ml of 7.5 N perchloric acid at 100°for 1 hr. NaOH (0.1 ml of 7.5 N) Fig. 1A) . The specific activity of deoxycytidine kinase, determined with [3H ]dC as substrate, increased 5-to 7-fold after infection of BHK cells with HSV-1 strains F and 2BB, and 20-to 30- fold after infection with HSV-2 strain G ( Table 2 ). In contrast to the results obtained with uninfected cell extracts,
[3H]BrdC was readily phosphorylated by extracts of HSVinfected BHK cells (Fig. 1A) deoxycytidylate deaminase was not active in these extracts. This is probably due to the instability of this enzyme in the absence of dCTP or high concentrations of dCMP (12) .
Because of the possible therapeutic significance of these results, the HEp-2 cell line was chosen to investigate the phosphorylation of [ (Fig. 1B) (1973) same protein (5) . Hay et al. (5) proposed that HSV induces a single pyrimidine deoxyribonucleoside kinase with two catalytic sites; one for the phosphorylation of dT and one for the phosphorylation of dC. Alternatively, HSV-induced thymidine kinase and deoxycytidine kinase could be activities of a single catalytic site. In contrast to the HSV-induced nucleoside kinase, deoxycytidine kinase and thymidine kinase appear to be genetically (21) and biochemically (22, 23) distinct enzymes in uninfected mammalian cells, and mammalian deoxycytidine kinase has a low affinity for dC analogs substituted with methyl, bromo, or iodo groups in the 5-position (11) . If a common catalytic site is involved in the phosphorylation of both dT and dC by the HSV-induced nucleoside kinase, then this enzyme might have a higher affinity for 5-substituted dC analogs than the deoxycytidine kinase of uninfected cells.
The difference in substrate specificity between HSV-induced and host-cell nucleoside kinases, reported in this study, might contribute to enhanced antiviral selectivity in the chemotherapy of HSV infections. The work of Kaufman and others (24, 25) has demonstrated the activity of IdU in the therapy of HSV infections of the cornea. IdC (14) , BrdU (26, 27) , and BrdC (27) appear to be as effective as IdU as inhibitors of HSV replication in tissue culture. Furthermore, BrdU (24) and IdC (28) are as active as IdU in the therapy of herpetic keratitis of the rabbit cornea. BrdC or IdC may be more selective antiviral agents than BrdU or IdU, since BrdC, and possibly IdC, would be phosphorylated by HSV-infected cells but not by uninfected cells. 5T-rifluoromethyldeoxyuridine has been reported to be a more potent antiviral agent than BrdU or IdU in the therapy of corneal HSV infections (29, 30) . If 5-trifluoromethyldeoxycytidine is phosphorylated by HSV-induced nucleoside kinase, then similar considerations would apply to the therapy of HSV infections with this nucleoside analog.
Human tissues contain high cytidine deaminase activities (31) . Therefore, inhibition of this enzyme with tetrahydrouridine would be required to prevent the deamination of BrdC to BrdU, which is toxic to normal as well as to HSVinfected cells. Tetrahydrouridine is an effective inhibitor in vivo of cytidine deaminase in mice (18, 32) , and previous work in this laboratory has shown that tetrahydrouridine reduces the utilization of BrdC for DNA synthesis by normal mouse tissues in vivo (10 (10) have shown that inhibition of cytidine deaminase by administration of tetrahydrouridine to mice increases the utilization of exogenous dC for DNA synthesis and increases the toxicity of 5-fluorodeoxycytidine, which is a good substrate for mouse deoxycytidine kinase (11) . The antineoplastic activity of cytosine arabinoside in mice is also increased by tetrahydrouridine administration (32) . These considerations suggest that more effective and selective chemotherapy of HSV infections may be achieved with BrdC, in combination with tetrahydrouridine, than is currently obtained with BrdU or IdU. It is possible that combination chemotherapy with tetrahydrouridine and BrdC or IdC would be effective for systemic HSV infections as well as for topical treatment of ocular or cutaneous infections.
